SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across AI neocloud stocks, fueled by concerns about financing costs and whether the sectors business models can deliver returns, has put NBIS in focus. Traders are split between viewing the drop as an overdone, oversold pullbackwith some citing NBISs stronger financial positionand expecting more downside amid lingering sector risks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound discussion after a sharp selloff, with some traders seeing the decline as overdone and others warning that CoreWeaves heavy debt and financing needs remain a risk. The debate centers on whether AI demand and contracted business can outweigh concerns about borrowing costs and the companys ability to fund its expansion.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is drawing attention after stronger-than-expected third-quarter results and a sharply higher 2027 adjusted EBITDA outlook. Bulls are highlighting the improved outlook and potential short-covering, while skeptics question whether operating gains can ease the companys substantial debt burden.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for the 80th death event in SELLASs blinded Phase 3 REGAL trialand the final analysis of its GPS treatment for AMLis driving attention amid share-price weakness. Bulls interpret the delay and upcoming ASH meeting as possible signs of extended survival or data disclosure, while skeptics say the timeline and CEOs comments prove nothing; no outcome has been confirmed, and traders also watch for SLS009 data.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention around AXPAXLIs prospects in wet AMD after competitor EyePoints trial setback. Some traders see fewer competitive threats and emphasize AXPAXLIs potential durability, while others argue the setback could fuel broader skepticism about TKI treatments; debate also centers on the companys pending NDA submission.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on XEs sharp post-IPO selloff, often blaming lockup-related share supply and weakness across nuclear and AI-linked stocks; concerns about the long path to commercialization and permitting also weigh on sentiment. Some holders remain bullish on Amazons backing and future data-center power demand, while others warn the selling may continue.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDAs clearance to expand Alpha Taus U.S. REGAIN recurrent-glioblastoma trial from 10 to 20 patients is drawing attention, alongside expectations for additional clinical data at the SNO meeting. Traders are broadly optimistic about the growing catalyst pipeline, while the early GBM results come from a very small cohort; completion of enrollment in the pancreatic IMPACT study is also contributing to the discussion.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results are drawing attention after wider mortgage spreads drove a sharp decline in book value and a reported loss, while earnings fell short of covering the monthly dividend. Traders are debating dividend sustainability and added risk from higher leverage, though some view the losses as largely unrealized and continue to favor the income stream.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech selloff, attributed by traders to rising-rate concerns, risk-off positioning and rotation away from smaller biotech stocks, is weighing on XBI. The community is split between expecting further weakness and viewing the sharp pullback as an oversold buying opportunity, with potential M&A and upcoming clinical catalysts cited as reasons for optimism.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound after a steep AI-infrastructure selloff has drawn attention to WULF, with traders highlighting CEO Paul Pragers CNBC defense of its power-and-data-center leasing model, which avoids owning rapidly depreciating chips, and bullish Morgan Stanley commentary. The community is split between viewing the move as a possible reversal and worrying that financing costs, leverage, and broader sector weakness could bring renewed selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.read more...

Invivyd Names Chairman Marc Elia CEO, Adds New Directors

(RTTNews) - Invivyd, Inc. (IVVD), the U.S. biotechnology company focused on antibody therapies for viral disease, Tuesday announced the appointment of Marc Elia as Chief Executive Officer and he will continue to serve as Chairman of the Board...

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of +6.67% and -13.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

RenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SkinHealth Systems Inc. (SKIN) Reports Q2 Loss, Lags Revenue Estimates

SkinHealth Systems Inc. (SKIN) delivered earnings and revenue surprises of +50.00% and -1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval

Equity

PEMGARDA’s emergency status will end on June 29, 2027, unless the company secures full FDA approval in the meantime.


IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%

Invivyd posted a first-quarter revenue of $13.7 million, sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data.

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -62.50% and -25.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Invivyd Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Invivyd said it is already in active talks with the FDA about next steps.</li><li>PEMGARDA received its emergency authorization in March 2024.</li><li>In 2025, PEMGARDA generated $53.4 million in net product revenue for Invivyd.</li></ul><p>Shares of Invivyd (IVVD) fell 6% on Monday after the company announced that it has received notice from the U.S. Food and Drug Administration (FDA) of the impending expiry of the emergency use authorization for its PEMGARDA preventive treatment</p><p>PEMGARDA’s emergency status will end on June 29, 2027, unless the company secures full FDA approval in the meantime.</p><p>Invivyd said it is already in active talks with the FDA about next steps and plans to pursue every available path to keep the treatment available for vulnerable patients.</p><h2 class="st-heading-2">PEMGARDA EUA And Demand</h2><p>PEMGARDA received its emergency authorization in March 2024 for use as a preventive option in adults and adolescents with moderate-to-severe immune compromise who are unlikely to respond adequately to COVID vaccines.</p><p>In 2025, PEMGARDA generated $53.4 million in net product revenue for Invivyd — more than double the $25.4 million recorded in its first partial year of sales in 2024.</p><h2 class="st-heading-2">IVVD Responds</h2><p>Invivyd board Chairman Marc Elia said the end of emergency status for COVID products is long overdue but stressed that PEMGARDA has compiled enough clinical and real-world data to support full approval.</p><p>“The EUA designation is not a product approval,” Elia noted. “We believe PEMGARDA has sufficient clinical and post-authorization data to support Biologics License Application submission and approval.”He added that the uncertainty created by the transition has been frustrating for the immunocompromised patients who rely on the treatment as a non-vaccine option.</p><h2 class="st-heading-2">How Did IVVD Retail Traders React?</h2><p>On Stocktwits, retail sentiment around IVVD stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.</p><p>According to data from Koyfin, all three analysts covering IVVD rate it a ‘Buy.’ The 12-month average price target on the stock is $10, representing a potential upside of over 1000% from the stock’s last closing price.</p><p><a href="https://stocktwits.com/symbol/IVVD">IVVD stock</a> has lost about 67% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-snaps-three-day-winning-streak-lockheed-martin-acquires-ultra-maritime-for-3-45-b/cZm11xAR7l8">LMT Stock Snaps Three-Day Winning Streak: Lockheed Martin Acquires Ultra Maritime For $3.45B</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

PEMGARDA’s emergency status will end on June 29, 2027, unless the company secures full FDA approval in the meantime.

iShares Core S&P Total U.S. Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.6186
Prev Close	$0.6688
Open	$0.6699
Dividend Yield	0.00%
50-Day Moving Average	$0.8198
Beta	1.61
Avg. Volume	6.98M
PE Ratio	-1.66

52-Week High	$3.07
52-Week Low	$0.5277
Market Capitalization	$182.34M
EPS (Annual)	-$0.3048
Price to Book	1.01
Revenue Per Employee	$437,918.03

Feed

News

Sentiment

Earnings

Fundamentals

Info

IVVD Fundamentals